Your search history is turned on.
Date: February 29, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Peter Rizakos, Chief Financial Officer of Braxia Scientific Corp., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the interim filings) of Braxia Scientific Corp. (the issuer) for the interim peri...
Braxia Scientific Reports Q3 2024 Financial Results TORONTO, ONTARIO February 29, 2024 Braxia Scientific Corp. (Braxia Scientific, or the Company), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its fi...
Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Roger McIntyre, Chief Executive Officer of Braxia Scientific Corp., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the interim filings) of Braxia Scientific Corp. (the issuer) for the interim per...
Microsoft Word - Braxia Scientific - MDA - December 31, 2023 - (FINAL) 1 Braxia Scientific Corp. Management Discussion & Analysis Prepared by Management (Expressed in Canadian Dollars) For the nine months ended December 31, 2023 and 2022 Braxia Scientific Corp. Managements Discussion and Analysis For the periods ended December 31, 2023 and 2022 2 Date: February 29...
Microsoft Word - Braxia Scientific - FS - December 31, 2023 (FINAL) Braxia Scientific Corp. Condensed Interim Consolidated Financial Statements For the three and nine months ended December 31, 2023 and 2022 Unaudited (Expressed in Canadian Dollars) NOTICE OF NO AUDITOR REVIEW Under National Instrument 51-102, Part 4 subsection 4.3 (3), if an auditor has not performed a review...
Date: January 15, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Braxia Scientific Reports Mandatory Conversion of Debentures TORONTO, ONTARIO January 15, 2024 Braxia Scientific Corp. (Braxia Scientific, or the Company), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the mand...
Date: December 11, 2023 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - Material Change Report -Dec 11 2023 FORM 51-102F3 Material Change Report ITEM 1 Name and Address of Company Braxia Scientific Corp (Braxia or the Company) 1430 Hurontario Street Mississauga, Ontario L5G 3H4 ITEM 2 Date of Material Changes (a) Change of Officers and Directors: November 28, 2023. ITEM 3 News Releases (a) N...
Date: November 30, 2023 Jurisdictions: Alberta, British Columbia, Ontario
Braxia Scientific Reports Q2 2024 Financial Results and Provides Corporate Update TORONTO, ONTARIO November 30, 2023 Braxia Scientific Corp. (Braxia Scientific, or the Company), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today ...
Date: November 29, 2023 Jurisdictions: Alberta, British Columbia, Ontario